TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2926224

Group type: EXPERIMENTAL
Intervention: Three-dimensional CT imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plain radiographs and computed tomography
Number of subjects: 20
Study: 785019

Group type: EXPERIMENTAL
Intervention: Antacid therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: No antacid therapy
Number of subjects: 48
Study: 31246632

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Enteral plus Total Parenteral Nutrition (EN+TPN)
Number of subjects: 45
Study: 28745578

Group type: EXPERIMENTAL
Intervention: G5 Mobile continuous glucose monitoring (CGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G5 Mobile CGM vs SMBG
Number of subjects: 0
Study: 26539982

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg∙kg‐1)
Number of subjects: 10
Study: 23384736

Group type: EXPERIMENTAL
Intervention: Metaphorical monitor
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard monitor
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metaphorical monitor with trend arrows
Number of subjects: 32

Group type: COMPARATOR
Intervention: Metaphorical monitor without trend arrows
Number of subjects: 32
Study: 22140661

Group type: EXPERIMENTAL
Intervention: Flapless protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flap protocol
Number of subjects: 60
Study: 19041111

Group type: EXPERIMENTAL
Intervention: Sewerage system connection (intervention group)
Number of subjects: 4179

Group type: COMPARATOR
Intervention: No sewerage system connection (control group)
Number of subjects: 4179
Study: 17874717

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) and physical therapy
Number of subjects: 42
Study: 15294263

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ICD therapy
Number of subjects: 0
Study: 11721321

Group type: EXPERIMENTAL
Intervention: OCA 1 (omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, twice daily for one week)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: OCA 2 (omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, twice daily for two weeks)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: OCM (omeprazole 20 mg, clarithromycin 500 mg, metronidazole 500 mg, twice daily for one week)
Number of subjects: 113
Study: 9248896

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen therapy
Number of subjects: 468

Group type: COMPARATOR
Intervention: Other known treatment modalities
Number of subjects: 468
Study: 7524833

Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.62
Number of subjects: 6

Group type: COMPARATOR
Intervention: 6% HES 200/0.5
Number of subjects: 6
Study: 2889555

Group type: EXPERIMENTAL
Intervention: Vecuronium (60 micrograms/kg bolus + 1 microgram/min/kg infusion) with halothane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium (60 micrograms/kg bolus + 1 microgram/min/kg infusion) with fentanyl anesthesia
Number of subjects: 0
Study: 30152527

Group type: COMPARATOR
Intervention: SENS-111 (100-500 mg single doses; 50-150 mg/day for 4 days; 200-250 mg/day for 7 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SENS-111 (100-200 mg/day)
Number of subjects: 100
Study: 23982695

Group type: EXPERIMENTAL
Intervention: Lyophilized black raspberries (BRBs) 45 g/d for 4 days followed by HFHC breakfast with BRBs
Number of subjects: 10

Group type: COMPARATOR
Intervention: HFHC breakfast without previous consumption of BRBs
Number of subjects: 10
Study: 26306861

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Smokers with early stage COPD
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 240

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 240
Study: 23867998

Group type: COMPARATOR
Intervention: Standard office hour appointment
Number of subjects: 9410

Group type: EXPERIMENTAL
Intervention: Office hour appointment with the option to change to out-of-hours appointment
Number of subjects: 9410

Group type: EXPERIMENTAL
Intervention: Weekday evening appointment
Number of subjects: 9410

Group type: EXPERIMENTAL
Intervention: Weekend appointment
Number of subjects: 9410
Study: 20966375

Group type: EXPERIMENTAL
Intervention: Standard Shape Up RI program plus video lessons on weight loss (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard Shape Up RI program plus video lessons, daily self-monitoring of weight, eating, and exercise, and computer-generated feedback (Study 2)
Number of subjects: 0
Study: 18940276

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 10548

Group type: COMPARATOR
Intervention: No lipid-lowering therapy
Number of subjects: 10548
Study: 15752106

Group type: EXPERIMENTAL
Intervention: Breath-freshening flavours in whole products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Products containing 0.1% (w/w) triclosan or 0.2% (w/w) zinc sulphate
Number of subjects: 0
Study: 14624424

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 1308
Study: 15089787

Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% tropicamide
Number of subjects: 30
Study: 10544423

Group type: EXPERIMENTAL
Intervention: Grunting during deadlifts
Number of subjects: 31

Group type: COMPARATOR
Intervention: No grunting during deadlifts
Number of subjects: 31
Study: 7546754

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 59

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 59
Study: 2224134

Group type: EXPERIMENTAL
Intervention: 12.0 Gy TBI
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 15.75 Gy TBI
Number of subjects: 71
Study: 705282

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (20 min/day of peroneal nerve stimulation)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional physiotherapy treatment (1 hour/day)
Number of subjects: 49
Study: 31012119

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 80
Study: 28166849

Group type: EXPERIMENTAL
Intervention: MeMOS condition (continuous feedback on patient progress to both therapist and supervisor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-Sup condition (feedback only to the therapist)
Number of subjects: 0
Study: 25959558

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose followed by 10 mg daily maintenance dose (n=19)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose followed by 90 mg twice daily maintenance dose (n=20)
Number of subjects: 39
Study: 23746674

Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CRT) to a dose of 66 Gy in 33 fractions over 6.5 weeks with concurrent cisplatin (100 mg/m(2) on days 1, 22 and 43)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with concomitant boost (CBRT) to a dose of 67.5 Gy in 40 fractions over 5 weeks
Number of subjects: 216

Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CRT)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy with concomitant boost (CBRT)
Number of subjects: 216
Study: 21085031

Group type: EXPERIMENTAL
Intervention: Preferred-intensity exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prescribed-intensity exercise
Number of subjects: 21
Study: 18940192

Group type: EXPERIMENTAL
Intervention: Low-normal readers
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-normal readers
Number of subjects: 0
Study: 16734237

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg IM
Number of subjects: 171

Group type: COMPARATOR
Intervention: Tramadol 100 mg IV
Number of subjects: 171
Study: 14652832

Group type: EXPERIMENTAL
Intervention: Supervised exercise and motivation class (once a week for 45 minutes for 6 months)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Exercise advice alone
Number of subjects: 59
Study: 11386782

Group type: EXPERIMENTAL
Intervention: n-butyl 2-cyanoacrylate tissue adhesive (Indermil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 50
Study: 9003618

Group type: EXPERIMENTAL
Intervention: Pretreatment Helicobacter pylori isolates
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pretreatment-posttreatment pairs
Number of subjects: 81
Study: 8428787

Group type: EXPERIMENTAL
Intervention: Reduced alcohol consumption (limited to zero or reduced as much as possible)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual alcohol drinking (self-reported 56.1 +/- 3.6 ml/day)
Number of subjects: 54
Study: 28200002

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 20 U
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 50 U
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 75 U
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Reconstituted abobotulinumtoxinA (aboBoNT‐A) 50 U
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 26297379

Group type: EXPERIMENTAL
Intervention: Web-based educational programme (3 hours)
Number of subjects: 67
Study: 25455987

Group type: EXPERIMENTAL
Intervention: MVA-H5-sfMR vaccine at 10^8 pfu
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MVA-H5-sfMR vaccine at 10^7 pfu
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Booster immunisation with MVA-H5-sfMR 10^8 pfu
Number of subjects: 80

Group type: COMPARATOR
Intervention: MVA-F6-sfMR (empty vector)
Number of subjects: 80
Study: 22928785

Group type: EXPERIMENTAL
Intervention: Danusertib 330 mg/m2 over 6 h i.v. on days 1, 8 and 15 (arm A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Danusertib 500 mg/m2 over 24 h i.v. on days 1 and 15 (arm B)
Number of subjects: 88
Study: 19887460

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/day)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (10 mg/kg/day for the first 14 days)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Prior azole exposure
Number of subjects: 201

Group type: COMPARATOR
Intervention: Survival at 12 weeks
Number of subjects: 201
Study: 18704249

Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate extended-release capsules 4 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate extended-release capsules 4 mg with behavioral therapy
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 305
Study: 15752098

Group type: EXPERIMENTAL
Intervention: n-butanol solutions (0 to 90,000 ppm)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: n-butanol
Number of subjects: 1
Study: 12525715

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 718
Study: 11109311

Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HRV analysis
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Echocardiography examination
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Late potentials
Number of subjects: 19
Study: 8779366

Group type: EXPERIMENTAL
Intervention: 2000 ml of Ringer lactate solution (crystalloid group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 500 ml of 6% hydroxyethyl starch + 1000 ml of Ringer lactate solution (colloid group)
Number of subjects: 22
Study: 1738219

Group type: EXPERIMENTAL
Intervention: Albumin supplementation with total parenteral nutrition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Total parenteral nutrition (control group)
Number of subjects: 12
Study: 6720727

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide/propranolol combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study: 31537194

Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure variability (BPV)
Number of subjects: 17916
Study: 28945652

Group type: EXPERIMENTAL
Intervention: Nonpreserved artificial teardrops with 0.3% of hyaluronic acid (Ocudry 0.3%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonpreserved 0.9% NaCl commercial saline solution
Number of subjects: 20
Study: 27165064

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor Votrient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mTOR blocker Afinitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Votrient and Afinitor
Number of subjects: 0
Study: 25072616

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Gestational weight gain below 0.1 kg/week
Number of subjects: 356

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) vs Efavirenz (EFV)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placental malaria
Number of subjects: 356
Study: 23359971

Group type: EXPERIMENTAL
Intervention: Chinese medical syndrome typing and treatment combined cold needle puncture drainage operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chinese medical syndrome typing and treatment combined unipolar electrocoagulation drilling technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (cold needle puncture drainage and unipolar electrocoagulation)
Number of subjects: 40
Study: 20572864

Group type: EXPERIMENTAL
Intervention: Stepwise excavation
Number of subjects: 314

Group type: COMPARATOR
Intervention: Direct capping
Number of subjects: 314

Group type: COMPARATOR
Intervention: Partial pulpotomy
Number of subjects: 314
Study: 17609407

Group type: EXPERIMENTAL
Intervention: Interstitial laser photocoagulation (ILP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Radioiodine ((131)I)
Number of subjects: 30
Study: 15613565

Group type: EXPERIMENTAL
Intervention: Ultrasound examination (US)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Early splinting
Number of subjects: 629
Study: 12502011

Group type: EXPERIMENTAL
Intervention: 15 mg mirtazapine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10463733

Group type: EXPERIMENTAL
Intervention: Cortical screw fixation with early mobilisation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Suture fixation with plaster boot immobilisation for six weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cortical screw fixation
Number of subjects: 30
Study: 7530173

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 in weeks 1 and 2, IFN 5 MU/m2 per day on days 1-5 in week 1, 5-FU 800 mg/m2 per day for 5 days, HU 500 mg every 12 h for 11 doses during week 2
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 during weeks 1 and 2, IFN 2.5 MU/m2 per day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (150 cGy twice daily during weeks 1 and 2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chemotherapy doses during hyperfractionated radiotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patients with all known disease confined to the radiotherapy field
Number of subjects: 49
Study: 2217661

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study: 712206

Group type: EXPERIMENTAL
Intervention: Urokinase (UUK)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tissue Culture Urokinase (TCUK)
Number of subjects: 30
Study: 30767961

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention with tailored messages and quarterly data on hazardous drug spills
Number of subjects: 396

Group type: COMPARATOR
Intervention: One-hour educational module on PPE use with quarterly reminders
Number of subjects: 396
Study: 29864035

Group type: EXPERIMENTAL
Intervention: Keratoconus patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Keratoconus patients with disease duration ≥5 years
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Keratoconus patients with BCVA ≥0.5 in the better eye
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Severe keratoconus patients (steep K reading ≥52)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (subjects with other ocular diseases)
Number of subjects: 30
Study: 26450657

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25019487

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Both groups (TVT and sham)
Number of subjects: 336
Study: 22752857

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fidaxomicin or Vancomycin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BI/NAP1/027 group and J/NAP2/001
Number of subjects: 90
Study: 20810109

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 18081224

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound with SonoVue (bolus injection 2.5 mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound with SonoVue
Number of subjects: 100
Study: 16741726

Group type: EXPERIMENTAL
Intervention: Temozolomide (75 mg/m²/day) for 6 weeks followed by a 2-week rest; Thalidomide (200 mg/day) increased by 100 mg/day weekly up to 400 mg/day (or 100 mg/day increased by 50 mg/day for patients >70 years up to 250 mg/day)
Number of subjects: 26
Study: 12052021

Group type: EXPERIMENTAL
Intervention: Counseling-based intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Skill-building intervention
Number of subjects: 80
Study: 9841816

Group type: EXPERIMENTAL
Intervention: Acyclovir and prednisone
Number of subjects: 0
Study: 8526581

Group type: EXPERIMENTAL
Intervention: Cultured skin substitutes (CSSs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Split-thickness autograft (STAG)
Number of subjects: 17
Study: 1883119

Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D daily
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 7047256

Group type: EXPERIMENTAL
Intervention: guanabenz (mean dose, 24 mg/day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: hydrochlorothiazide (50 or 100 mg/day; mean, 70 mg/day)
Number of subjects: 204
Study: 30747820

Group type: EXPERIMENTAL
Intervention: Revised standard-of-care procedure with continuous education and individual teaching
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional care without additional education
Number of subjects: 66
Study: 28323668

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 35
Study: 25880969

Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter (IPC) plus talc sclerosant
Number of subjects: 154

Group type: COMPARATOR
Intervention: Indwelling pleural catheter (IPC) alone
Number of subjects: 154
Study: 22707003

Group type: EXPERIMENTAL
Intervention: Anterior trocar-guided transvaginal mesh surgery
Number of subjects: 99

Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 99
Study: 20825791

Group type: EXPERIMENTAL
Intervention: Secobarbital 100 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19214338

Group type: EXPERIMENTAL
Intervention: Higher protein diet (1.2 +/- 0.0 g protein x kg(-1) x d(-1))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lower protein diet (0.9 +/- 0.1 g protein x kg(-1) x d(-1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both higher and lower protein diets
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher protein intake achieved by consuming more eggs, meats, and dairy foods
Number of subjects: 36
Study: 16772707

Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 15327757

Group type: EXPERIMENTAL
Intervention: Transsylvian approach (TS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transcortical approach (TC)
Number of subjects: 80
Study: 10378391

Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg t.i.d.) for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 12
Study: 8679756

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 1888695

Group type: COMPARATOR
Intervention: Benazepril (10 mg once daily)
Number of subjects: 10
Study: 6134981

Group type: EXPERIMENTAL
Intervention: Selenium levels in serum (mean 0.129 +/- SEM 0.002 micrograms/ml)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Selenium levels in serum (mean 0.136 +/- SEM 0.002 micrograms/ml)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Lowest quintile of serum selenium
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Lowest tertile of selenium
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Low selenium levels
Number of subjects: 321
Study: 31717406

Group type: EXPERIMENTAL
Intervention: Physical activity intervention based on self‐determination theory and the transtheoretical model
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 30133928

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FOS) 3 g PO every 10 days + trimethoprim‐sulfamethoxazole (TMP‐SMX, 160/800 mg) three times per week (Group 1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMX, 160/800 mg) daily (Group 2)
Number of subjects: 67